Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1

Tomohiro Umezu, Hiroko Tadokoro, Kenko Azuma, Seiichiro Yoshizawa, Kazuma Ohyashiki, Junko H. Ohyashiki

Blood (2014) 124 (25): 3748–3757.

https://doi.org/10.1182/blood-2014-05-576116

Published: 2014

Includes: Supplemental data

Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2014) 124 (21): 1797.

https://doi.org/10.1182/blood.V124.21.1797.1797

Published: 2014

Journal Articles

Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients

Seiichiro Yoshizawa, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Shinsuke Iida, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1879.

https://doi.org/10.1182/blood.V122.21.1879.1879

Published: 2013

Journal Articles

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

Yuko Tanaka, MD, Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yoshikazu Ito, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1894.

https://doi.org/10.1182/blood.V122.21.1894.1894

Published: 2013

Journal Articles

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Seiichiro Katagiri, MD, Tetsuzo Tauchi, MD, Tomohiro Umezu, PhD, Kazuhiro Ohtsuki, PhD, Kenichi Tadokoro, Yoshinori Yamamoto, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 4021.

https://doi.org/10.1182/blood.V122.21.4021.4021

Published: 2013

Journal Articles

Activation Levels of Natural Killer Cells and CD8 + T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients

Seiichiro Katagiri, MD, Izuru Mizoguchi, PhD, Takayuki Yoshimoto, PhD, Junichiro Mizuguchi, MD, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 3745.

https://doi.org/10.1182/blood.V120.21.3745.3745

Published: 2012

Journal Articles

Age-Related Decrease of Human CD8 + T-Cell Mir-92a Level Correlated with Reduction of naïve T Lymphocyte

Michiyo Ohyashiki, MD, Junko H Ohyashiki, MD, PhD, Ayako Hirota, Chiaki Kobayashi, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 2186.

https://doi.org/10.1182/blood.V118.21.2186.2186

Published: 2011

Journal Articles

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder

Sei-ichiro Yoshizawa, MD, Junko H Ohyashiki, MD, PhD, Michiyo Ohyashiki, MD, Tomohiro Umezu, PhD, Kenshi Suzuki, MD, PhD, Atsushi Inagaki, MD, PhD, Shinsuke Iida, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 2871.

https://doi.org/10.1182/blood.V118.21.2871.2871

Published: 2011

Journal Articles

Increased NK Cells and Decreased CD3 + CD8 + CD62L + T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib

Kazuma Ohyashiki, MD, PhD, Sei-ichiro Katagiri, MD, Tetsuzo Tauchi, MD, PhD, Junko H Ohyashiki, MD, PhD, Yasuhiro Maeda, MD, PhD, Itaru Matsumura, MD, PhD, Taiichi Kyo, MD

Blood (2011) 118 (21): 1697.

https://doi.org/10.1182/blood.V118.21.1697.1697

Published: 2011

Journal Articles

Mechanism of Action of MK-0457 Efficacy in Monotherapy and in Combination with Vorinostat in Wild Type and T315I Mutant BCR/ABL Positive Leukemia Cells.

Seiichi Okabe, MD, PhD, Tetsuzo Tauchi, MD., Ph.D, Junko H. Ohyashiki, MD., Ph.D, Kazuma Ohyashiki

Blood (2007) 110 (11): 1051.

https://doi.org/10.1182/blood.V110.11.1051.1051

Published: 2007

Journal Articles

Estimating Immunoregulatory Gene Networks in Human Herpesvirus Type 6 (HHV-6)-Infected T Cells.

Tomoiku Takaku, MD, Junko H. Ohyashiki, MD, Yu Zhang, MD, Kazuma Ohyashiki, MD

Blood (2005) 106 (11): 2381.

https://doi.org/10.1182/blood.V106.11.2381.2381

Published: 2005

Journal Articles

Identification and Functional Significance of Genes Regulated by Structurally Different ABL Kinase Inhibitors.

Kousuke Nunoda, MD, Tetsuzo Tauchi, MD, Tomoiku Takaku, MD, Masahiko Sumi, MD, Seiichi Okabe, MD, Goro Sashida, MD, Daigo Akahane, MD, Junko H. Ohyashiki, MD, Kazuma Ohyashiki, MD

Blood (2005) 106 (11): 2860.

https://doi.org/10.1182/blood.V106.11.2860.2860

Published: 2005

Journal Articles

Activity of ABT-737, an Inhibitor of BCL-2 Family Proteins, in Imatinib- or Dasatinib-Resistant CML Cells: Involvement of BCL-2 Family Proteins for Drug Resistance.

Tetsuzo Tauchi, MD, Kousuke Nunoda, MD, Tomoiku Takaku, MD, Masahiko Sumi, MD, Daigo Akahane, MD, Goro Sashida, MD, Junko H. Ohyashiki, MD, Kazuma Ohyashiki, MD

Blood (2005) 106 (11): 3364.

https://doi.org/10.1182/blood.V106.11.3364.3364

Published: 2005

Journal Articles

Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing TF-1 Cells.

Seiichi Okabe, Tetsuzo Tauchi, Akihiro Nakajima, Goro Sashida, Masahiko Sumi, Akihiko Gotoh, Hal E. Broxmeyer, Junko H. Ohyashiki, Kazuma Ohyashiki

Blood (2005) 106 (11): 4845.

https://doi.org/10.1182/blood.V106.11.4845.4845

Published: 2005

Journal Articles

Additional Cytogenetic Changes and Prior Genotoxic Exposure Predict Unfavorable Prognosis in Myelodysplastic Syndromes and Acute Myeloid Leukemia with der(1;7)(q10;p10).

Kazuma Ohyashiki, MD, Hui-Hua Hsiao, MD, Goro Sashida, MD, Yoshikazu Ito, MD, Junko H. Ohyashiki, MD

Blood (2005) 106 (11): 4894.

https://doi.org/10.1182/blood.V106.11.4894.4894

Published: 2005

Journal Articles

Myelodysplastic Syndromes with Myelofibrosis May Be a Target for the JAK2 V617F Tyrosine Kinase Mutation.

Kazuma Ohyashiki, MD, Yasuo Aota, MD, Akihiko Gotoh, MD, Keisuke Miyazawa, MD, Yukihiko Kimura, MD, Junko H. Ohyashiki, MD

Blood (2005) 106 (11): 4895.

https://doi.org/10.1182/blood.V106.11.4895.4895

Published: 2005

Journal Articles

Transcriptional Profiling of Epstein-Barr Virus (EBV) Genes and Host Cellular Genes in Nasal NK/T-Cell Lymphoma and Chronic Active EBV Infection.

Yu Zhang, MD, Junko H. Ohyashiki, MD, Tomoiku Takaku, MD, Norio Shimizu, PhD, Kazuma Ohyashiki, MD

Blood (2005) 106 (11): 4359.

https://doi.org/10.1182/blood.V106.11.4359.4359

Published: 2005

Journal Articles

Specific Inhibition of hTERT by shRNA Sensitizes for Imatinib Mesylate in BCR-ABL-Positive Cells.

Goro Sashida, M.D., Tetsuzo Tauchi, M.D., Masahiko Sumi, M.D., Akihiro Nakajima, M.D., Junko H. Ohyashiki, M.D., Kazuma Ohyashiki, M.D.

Blood (2004) 104 (11): 4339.

https://doi.org/10.1182/blood.V104.11.4339.4339

Published: 2004

Journal Articles

Telomerase Inhibition with a Novel G-Quadruplex-Interactive Agent, Telomestatin: In Vitro and In Vivo Studies in Acute Leukemia.

Tetsuzo Tauchi, MD, Kazuo Shin-ya, PhD, Goro Sashida, MD, Masahiko Sumi, MD, Akihiro Nakajima, MD, Junko H. Ohyashiki, MD, Kazuma Ohyashiki, MD

Blood (2004) 104 (11): 3391.

https://doi.org/10.1182/blood.V104.11.3391.3391

Published: 2004

NARROW

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Activation Levels of Natural Killer Cells and CD8 + T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients

Age-Related Decrease of Human CD8 + T-Cell Mir-92a Level Correlated with Reduction of naïve T Lymphocyte

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder

Increased NK Cells and Decreased CD3 + CD8 + CD62L + T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib

Mechanism of Action of MK-0457 Efficacy in Monotherapy and in Combination with Vorinostat in Wild Type and T315I Mutant BCR/ABL Positive Leukemia Cells.

Estimating Immunoregulatory Gene Networks in Human Herpesvirus Type 6 (HHV-6)-Infected T Cells.

Identification and Functional Significance of Genes Regulated by Structurally Different ABL Kinase Inhibitors.

Activity of ABT-737, an Inhibitor of BCL-2 Family Proteins, in Imatinib- or Dasatinib-Resistant CML Cells: Involvement of BCL-2 Family Proteins for Drug Resistance.

Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing TF-1 Cells.

Additional Cytogenetic Changes and Prior Genotoxic Exposure Predict Unfavorable Prognosis in Myelodysplastic Syndromes and Acute Myeloid Leukemia with der(1;7)(q10;p10).

Myelodysplastic Syndromes with Myelofibrosis May Be a Target for the JAK2 V617F Tyrosine Kinase Mutation.

Transcriptional Profiling of Epstein-Barr Virus (EBV) Genes and Host Cellular Genes in Nasal NK/T-Cell Lymphoma and Chronic Active EBV Infection.

Specific Inhibition of hTERT by shRNA Sensitizes for Imatinib Mesylate in BCR-ABL-Positive Cells.

Telomerase Inhibition with a Novel G-Quadruplex-Interactive Agent, Telomestatin: In Vitro and In Vivo Studies in Acute Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only